| Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy (NCT05420480) | Shanghai Zhongshan Hospital | 2022-07-01 |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (NCT05252078) | Jiangxi Provincial Cancer Hospital | 2022-06-02 |
| Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC (NCT05213312) | Shanghai Zhongshan Hospital | 2022-06-01 |
| Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma (NCT05028725) | University of California, San Francisco | 2022-05-16 |
| Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (NCT05394415) | Jiangsu Cancer Institute & Hospital | 2022-05-01 |
| A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC (NCT05317325) | Sichuan University | 2022-04-01 |
| Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) (NCT05038813) | The First Affiliated Hospital of Zhengzhou University | 2022-03-14 |
| Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC (NCT05287880) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2022-03-10 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (NCT05170256) | Morten Mau-Sørensen | 2022-02-04 |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392) | City of Hope Medical Center | 2022-01-25 |
| Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC (NCT05469061) | The First Affiliated Hospital with Nanjing Medical University | 2022-01-01 |
| Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora (NCT05199649) | The First Affiliated Hospital of Soochow University | 2021-12-01 |
| A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC (NCT04514835) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade (NCT04984018) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) (NCT04807673) | Tianjin Medical University Cancer Institute and Hospital | 2021-12-01 |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT03766178) | The First Affiliated Hospital of Zhengzhou University | 2021-09-01 |
| PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT05007145) | Fujian Cancer Hospital | 2021-08-15 |
| RAPA-201 Therapy of Solid Tumors (NCT05144698) | Rapa Therapeutics LLC | 2021-08-01 |
| Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (NCT04880811) | Peking University | 2021-07-01 |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (NCT05189730) | Sichuan Cancer Hospital and Research Institute | 2021-07-01 |
| Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NCT05028231) | Tongji Hospital | 2021-06-05 |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (NCT04868877) | Merus B.V. | 2021-04-28 |
| JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (NCT04721223) | Jacobio Pharmaceuticals Co., Ltd. | 2021-04-26 |
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. (NCT05044728) | Sichuan Cancer Hospital and Research Institute | 2021-04-01 |
| An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody (NCT04866381) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-01 |
| Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (NCT04732494) | BeiGene | 2021-03-31 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma (NCT04851132) | Chinese Academy of Medical Sciences | 2021-03-11 |
| Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT04813406) | Henan Provincial People's Hospital | 2021-03-01 |
| A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) (NCT04767295) | Hunan Cancer Hospital | 2021-03-01 |
| A Clinical Trial of Esophagectomy for Esophageal Carcinoma (NCT06691503) | Sun Yat-sen University | 2021-03-01 |
| Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (NCT04844385) | Sun Yat-sen University | 2021-02-20 |
| Esophageal cAncer Screening Trial (NCT04609813) | Changhai Hospital | 2021-01-01 |
| Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma (NCT05174325) | The First Affiliated Hospital of Soochow University | 2020-12-01 |
| Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (NCT05740995) | Shanghai Zhongshan Hospital | 2020-12-01 |
| Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (NCT04460352) | Karolinska University Hospital | 2020-11-27 |
| Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (NCT04666090) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-11-23 |
| Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (NCT04550260) | AstraZeneca | 2020-10-19 |
| CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer (NCT04481100) | Hangzhou Cancer Hospital | 2020-10-01 |
| A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (NCT04543617) | Hoffmann-La Roche | 2020-09-28 |
| Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (NCT04584008) | Peking University | 2020-09-23 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04644250) | Wei Ren | 2020-09-01 |
| Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients (NCT04548440) | Sun Yat-Sen University Cancer Center | 2020-08-31 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (NCT04506138) | Zhejiang Cancer Hospital | 2020-08-11 |
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04435197) | Ruijin Hospital | 2020-08-11 |
| The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer (NCT04212598) | Wuhan University | 2020-08-03 |
| Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer (NCT04503967) | Shanghai Zhongshan Hospital | 2020-08-01 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China (NCT04121286) | Allist Pharmaceuticals, Inc. | 2020-07-14 |
| Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) (NCT04389177) | Tianjin Medical University Cancer Institute and Hospital | 2020-07-08 |
| A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC (NCT04328948) | National Cancer Center, Japan | 2020-07-01 |
| Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE) (NCT04440332) | Sichuan Cancer Hospital and Research Institute | 2020-07-01 |
| Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel (NCT04699994) | Keio University | 2020-06-25 |
| A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom (NCT04936399) | Bristol-Myers Squibb | 2020-06-25 |
| Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma (NCT04568200) | Peking Union Medical College Hospital | 2020-06-19 |
| HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma (NCT06184841) | Peking University Cancer Hospital & Institute | 2020-06-18 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction (NCT04229524) | Sichuan Cancer Hospital and Research Institute | 2020-06-01 |
| Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NCT05302011) | Peking Union Medical College Hospital | 2020-06-01 |
| Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) (NCT04764227) | Fudan University | 2020-05-30 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT04390958) | Chinese Academy of Medical Sciences | 2020-05-15 |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04177797) | Sichuan Cancer Hospital and Research Institute | 2020-03-20 |
| Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC (NCT04229537) | Sinocelltech Ltd. | 2020-03-01 |
| Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. (NCT04229459) | Baruch Brenner | 2020-02-16 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy (NCT04764643) | Xijing Hospital of Digestive Diseases | 2020-02-01 |
| Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma (NCT04380480) | Sun Yat-sen University | 2020-02-01 |
| Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma (NCT04275986) | Chinese Academy of Medical Sciences | 2020-01-20 |
| Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma (NCT04225364) | Guangzhou Institute of Respiratory Disease | 2020-01-17 |
| Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT04229849) | Henan Cancer Hospital | 2020-01-01 |
| Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction (NCT04224363) | Shandong University | 2020-01-01 |
| Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC (NCT04759235) | RenJi Hospital | 2020-01-01 |
| an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer (NCT07605663) | Fudan University | 2020-01-01 |
| To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy (NCT04199832) | Tianjin Medical University Cancer Institute and Hospital | 2019-12-20 |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) (NCT04290806) | iOMEDICO AG | 2019-12-04 |
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (NCT04138212) | Henan Cancer Hospital | 2019-10-22 |
| Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions (NCT04170257) | Peking University Cancer Hospital & Institute | 2019-10-18 |
| Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC (NCT03985046) | Fudan University | 2019-10-10 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. (NCT04063683) | Henan Cancer Hospital | 2019-10-07 |
| A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC (NCT03817658) | The First Affiliated Hospital of Zhengzhou University | 2019-10-01 |
| Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma (NCT04054518) | Tiago Biachi | 2019-10-01 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors (NCT04045496) | Jacobio Pharmaceuticals Co., Ltd. | 2019-09-26 |
| A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. (NCT04084158) | Zhejiang Cancer Hospital | 2019-09-07 |
| Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma (NCT04009265) | Fujian Medical University Union Hospital | 2019-08-23 |
| Neoadjuvant Nivolumab for Operable Esophageal Carcinoma (NCT03987815) | Samsung Medical Center | 2019-08-01 |
| KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma (NCT03925870) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-06-21 |
| A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (NCT03958890) | Shanghai Henlius Biotech | 2019-06-19 |
| KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (NCT03927495) | Shanghai Chest Hospital | 2019-05-22 |
| Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer (NCT03946969) | The First Affiliated Hospital with Nanjing Medical University | 2019-05-09 |
| A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer (NCT03940001) | Zhejiang Cancer Hospital | 2019-05-01 |
| Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) (NCT03940976) | Peking University | 2019-04-28 |
| Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT03964753) | Hebei Medical University Fourth Hospital | 2019-04-24 |
| Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer (NCT03913182) | Shanghai Chest Hospital | 2019-04-02 |
| Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer (NCT03922230) | Nanfang Hospital, Southern Medical University | 2019-03-01 |
| Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC (NCT04514822) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2019-03-01 |
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma (NCT03857763) | Hebei Medical University Fourth Hospital | 2019-03-01 |
| Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo) (NCT03833466) | Peking University | 2019-02-05 |